Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient's cells.

PHILADELPHIA, March 18, 2026--iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo ...

INSTALL results showed successful and safe non-viral insertion of large genetic payloads in the livers of mice when delivered by lipid nanoparticles (LNPs). In contrast, mice experienced fatal immune ...

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient’s cells. However, most genetic disorders are caused by dozens or even thousands of ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...

This episode includes a 4D simulation, a new gene insertion technique, dementia blood biomarkers, and updates from uniQure and Moderna.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, ...

- Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, and ...